The EAHP Board, elected for three-year terms, oversees the association’s activities. Comprising directors responsible for core functions, it meets regularly to implement strategic goals. Supported by EAHP staff, the Board controls finances, coordinates congress organization, and ensures compliance with statutes and codes of conduct.
EAHP COVID-19 Resource Centre | European bodies
European Medicines Agency
- Dedicated webpage on COVID-19
EMA has put together a dedicated website which summarized information on COVID-19. - EMA Communication: Reporting suspected side effects of medicines in patients with COVID-19
EMA and the national competent authorities are reminding healthcare professionals and patients with confirmed or suspected coronavirus disease (COVID-19) to report suspected side effects that they experience with any of the medicines they are taking.
European Directorate for the Quality of Medicines & HealthCare (EDQM)
- Information on licensed products as well as extemporaneous preparations which may be suitable for treatment of paediatric patients with COVID-19
The European Paediatric Formulary Working Party at the EDQM compiled existing knowledge on paediatric formulations for active substances which are under investigation for the treatment of COVID-19 as well as known authorised medicinal products. This information might also be useful for other patient groups. Information on Chloroquine, Hydroxychloroquine and Lopinavir/Ritonavir is currently available. - EDQM’s contributions to the protection of public health in the COVID-19 pandemic: latest information
EDQM shared information on the preparedness of the Directorate as well as on information that has been made available to address the COVID-19 pandemic.
The disclaimer for the EAHP COVID-19 Resource Centre can be found here